References
Alzheimer's Association (2012). What Is Alzheimer's?, Alzheimer's Association, Chicago, IL, USA. Accessed on 02-10-2012: http://www.alz.org/alzheimers_disease_what_is_alzheimers.asp#.
Alzheimer's Disease Research (2012). Alzheimer's Symptoms & Stages, American Health Assistance Foundation, Clarksburg, Maryland, USA. Accessed on 02-10-2012: http://www.ahaf.org/alzheimers/about/symptomsandstages.html.
Berchtold NC, Cotman CW (1998). Evolution in the conceptualization of dementia and Alzheimer's disease: Greco-Roman period to the 1960s. Neurobiol. Aging.19(3):173–189.
Citron M (2004). β-Secretase inhibition for the treatment of Alzheimer's disease – promise and challenge. Trends in Pharmacological Sciences 25(2):92-97.
Irvine GB, El-Agnaf OM, Shankar GM, Walsh GM (2008). Protein Aggregation in the Brain: The Molecular Basis for Alzheimer’s and Parkinson’s Diseases. Molecular Medicine 14(7-8):451-464.
John V, Beck JP, Bienkowski MJ, Sinha S, Heinrikson RL (2003). Human β-Secretase (BACE) and BACE Inhibitors. Journal of Medicinal Chemistry 46(22):4625-4630.
Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S et al. (2012). A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline. Nature 488(7409):96-99.
Price DL, Borchelt DR, Sisodia SS (1993). Alzheimer disease and the prion disorders amyloid β-protein and prion protein amyloidoses. Proceedings of the National Academy of Sciences of the United States of America 90:6381-6384.
Prusiner SB, Scott M, Foster D, Pan KM, Groth D, Mirenda C et al. (1990). Transgenetic studies implicate interactions between homologous PrP isoforms in scrapie prion replication. Cell 63(4): 673-686.
Sawaya MR, Sambashivan S, Nelson R, Ivanova MI, Sievers SA, Apostol MI et al. (2007). Atomic structures of amyloid cross-b spines reveal varied steric zippers. Nature 447:453-457.
Schramm VL (2005). Enzymatic transition states and transition state analogues. Current Opinion in Structural Biology 15(6):604-613.
Selkoe DJ (2001). Alzheimer’s Disease: Genes, Proteins, and Therapy. Physiological Reviews 81(2):741-766.
Walsh GM, Selkoe DJ (2007). Aβ Oligomers – a decade of discovery. Journal of Neurochemistry 101:1172–1184.
Wang H, Bakshi K, Frankfurt M, Stucky A, Goberdhan M, Shah SM et al. (2012). PTI-125 Reduces Amyloid-related Alzheimer’s Pathogenesis by Targeting Filamin A. The Journal of Neuroscience 32(29): 9773–9784.
Alzheimer's Disease Research (2012). Alzheimer's Symptoms & Stages, American Health Assistance Foundation, Clarksburg, Maryland, USA. Accessed on 02-10-2012: http://www.ahaf.org/alzheimers/about/symptomsandstages.html.
Berchtold NC, Cotman CW (1998). Evolution in the conceptualization of dementia and Alzheimer's disease: Greco-Roman period to the 1960s. Neurobiol. Aging.19(3):173–189.
Citron M (2004). β-Secretase inhibition for the treatment of Alzheimer's disease – promise and challenge. Trends in Pharmacological Sciences 25(2):92-97.
Irvine GB, El-Agnaf OM, Shankar GM, Walsh GM (2008). Protein Aggregation in the Brain: The Molecular Basis for Alzheimer’s and Parkinson’s Diseases. Molecular Medicine 14(7-8):451-464.
John V, Beck JP, Bienkowski MJ, Sinha S, Heinrikson RL (2003). Human β-Secretase (BACE) and BACE Inhibitors. Journal of Medicinal Chemistry 46(22):4625-4630.
Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S et al. (2012). A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline. Nature 488(7409):96-99.
Price DL, Borchelt DR, Sisodia SS (1993). Alzheimer disease and the prion disorders amyloid β-protein and prion protein amyloidoses. Proceedings of the National Academy of Sciences of the United States of America 90:6381-6384.
Prusiner SB, Scott M, Foster D, Pan KM, Groth D, Mirenda C et al. (1990). Transgenetic studies implicate interactions between homologous PrP isoforms in scrapie prion replication. Cell 63(4): 673-686.
Sawaya MR, Sambashivan S, Nelson R, Ivanova MI, Sievers SA, Apostol MI et al. (2007). Atomic structures of amyloid cross-b spines reveal varied steric zippers. Nature 447:453-457.
Schramm VL (2005). Enzymatic transition states and transition state analogues. Current Opinion in Structural Biology 15(6):604-613.
Selkoe DJ (2001). Alzheimer’s Disease: Genes, Proteins, and Therapy. Physiological Reviews 81(2):741-766.
Walsh GM, Selkoe DJ (2007). Aβ Oligomers – a decade of discovery. Journal of Neurochemistry 101:1172–1184.
Wang H, Bakshi K, Frankfurt M, Stucky A, Goberdhan M, Shah SM et al. (2012). PTI-125 Reduces Amyloid-related Alzheimer’s Pathogenesis by Targeting Filamin A. The Journal of Neuroscience 32(29): 9773–9784.
Copyright ©2012 by SW Wong, E Lo and N Rodrigues. All rights reserved.
Disclaimer: The information in this website is for general informational purposes only and is not presented by professional neurologists or any experts in the field. While we endeavor to maintain the accuracy and reliability of the information, we disclaim any liabilities for any consequences due to reliance on any erroneous information in our website.